Comparison

AOD-9604 vs Setmelanotide

Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research

AOD-9604

Also: Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191

Clinical Trials

A modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full GH.

Weight LossHuman Trials
Setmelanotide

Also: Imcivree, RM-493

FDA Approved

An MC4R agonist for rare genetic obesity disorders. FDA approved for specific gene mutations causing obesity.

Weight LossFDA Approved

Key Comparison Insights

  • Setmelanotide is FDA approved, while AOD-9604 remains in research stages.
  • Both peptides belong to the Weight Loss category, suggesting similar primary applications.
  • Setmelanotide has stronger research evidence (FDA Approved) compared to AOD-9604 (Human Trials).

Detailed Comparison

AttributeAOD-9604Setmelanotide
CategoryWeight LossWeight Loss
FDA StatusNot FDA ApprovedFDA Approved
Clinical Status
Pre
I
II
III
IV
FDA
Pre
I
II
III
IV
FDA
Mechanism of ActionAOD-9604 mimics the lipolytic (fat-burning) effects of growth hormone without affecting blood sugar or tissue growth. It stimulates lipolysis and inhibits lipogenesis by interacting with beta-3 adrenergic receptors on fat cells.Setmelanotide activates melanocortin-4 receptors (MC4R) in the hypothalamus, restoring the satiety signaling pathway that is disrupted in certain genetic obesity syndromes. Works downstream of leptin signaling.
Common Dosing
300 mcg daily
Once daily, usually morning fasted
2-3 mg daily
Once daily
AdministrationSubcutaneous injection or oral (studied both)Subcutaneous injection daily
Typical Duration12-24 weeks in studiesLong-term / chronic use
Best Time to TakeMorning (fasted)Before bed or morning (fasted)
Possible Side Effects
May vary by individual
  • Generally very well-tolerated
  • Injection site reactions
  • Mild headache
  • Dizziness
  • Does NOT produce typical HGH side effects
  • +2 more
  • Skin hyperpigmentation (67-83%)
  • Injection site reactions
  • Nausea
  • Spontaneous erections in males
  • Priapism risk
  • +2 more
Research SummaryClinical trials showed modest weight loss effects but failed to meet primary endpoints for FDA approval. Some studies show cartilage regeneration potential. Research demonstrates safety profile similar to placebo with no significant GH-like side effects.Approved for POMC, PCSK1, and LEPR deficiency obesity. Studies show significant weight loss in these specific populations where other treatments fail. Precision medicine approach.

Frequently Asked Questions: AOD-9604 vs Setmelanotide

What is the difference between AOD-9604 and Setmelanotide?

AOD-9604 is a weight loss peptide that a modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full gh. Setmelanotide is a weight loss peptide that an mc4r agonist for rare genetic obesity disorders. fda approved for specific gene mutations causing obesity. The main differences lie in their mechanisms of action and clinical applications.

Which is better, AOD-9604 or Setmelanotide?

Neither is universally "better" - the choice depends on your specific goals. AOD-9604 is typically used for weight loss purposes, while Setmelanotide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.

Can AOD-9604 and Setmelanotide be used together?

Some peptide protocols combine multiple compounds for synergistic effects. However, using AOD-9604 and Setmelanotide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.

Related Comparisons

View Full Peptide Profiles

Educational Information Only

This comparison of AOD-9604 and Setmelanotide is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.